Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Sales (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Return on Sales for 11 consecutive years, with 4.01% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 577.0% to 4.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.09% through Dec 2025, up 232.0% year-over-year, with the annual reading at 6.09% for FY2025, 232.0% up from the prior year.
  • Return on Sales for Q4 2025 was 4.01% at Intellia Therapeutics, up from 7.6% in the prior quarter.
  • The five-year high for Return on Sales was 2.11% in Q4 2021, with the low at 238.81% in Q3 2021.
  • Average Return on Sales over 5 years is 19.96%, with a median of 7.87% recorded in 2023.
  • The sharpest move saw Return on Sales tumbled -23756bps in 2021, then skyrocketed 23101bps in 2022.
  • Over 5 years, Return on Sales stood at 2.11% in 2021, then decreased by -26bps to 2.65% in 2022, then tumbled by -360bps to 12.19% in 2023, then increased by 20bps to 9.77% in 2024, then skyrocketed by 59bps to 4.01% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 4.01%, 7.6%, and 7.2% for Q4 2025, Q3 2025, and Q2 2025 respectively.